


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Starsportned

STAR SPORTS MEDICINE CO., LTD.

北京天星醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01609)

VOLUNTARY ANNOUNCEMENT

SELECTED FOR INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX

This announcement is made by Star Sports Medicine Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis, for the purpose of providing the shareholders and potential investors of the Company with the latest information of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, according to the review results of the Hang Seng Family of Indexes for the second quarter of 2026 announced by Hang Seng Indexes Company Limited on August 21, 2026, the Company has been selected and will be included as a constituent of the Hang Seng Composite Index by Hang Seng Indexes Company Limited with effect from September 7, 2026. Following its inclusion as a constituent of the Hang Seng Composite Index, the shares of the Company are expected to meet the inclusion criteria for trading under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.

The Board considers that being selected for inclusion in the Hang Seng Composite Index represents significant progress in the Company’s capital market development following its listing, which is expected to further enhance the Company’s visibility and investability in the Hong Kong capital market and broaden its coverage among potential investors. The Company will continue to focus on product innovation, creation of clinical value and global business development in the field of sports medicine, and continuously improve its operational quality, so as to create long-term value for the shareholders and investors of the Company.

By order of the Board
Star Sports Medicine Co., Ltd.
Mr. Dong Wenxing
Chairman of the Board and Executive Director

Hong Kong, August 24, 2026

As at the date of this announcement, the Board comprises Mr. Dong Wenxing and Mr. He Lu as executive Directors; Ms. Zhang Di, Mr. Chang Xi, Mr. David Guowei Wang, Ms. Yi Lin and Mr. Zhou Quan as non-executive Directors; and Mr. Lyu Zhenlin, Mr. Deng Yu, Mr. Liu Baojie and Mr. Wang Chunfei as independent non-executive Directors.